Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + cyclophosphamide + cisplatin
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination chemotherapy regimen, consisting of doxorubicin, cyclophosphamide, and cisplatin, is being investigated by West China Hospital in a Phase 2 clinical trial for the treatment of locally advanced or metastatic poorly differentiated or anaplastic thyroid cancer. The study utilizes a precision medicine approach where patient-derived tumor organoids are used for in-vitro drug sensitivity testing to guide the selection of the most effective chemotherapy regimen for individual patients. Doxorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II; cyclophosphamide is an alkylating agent that forms DNA cross-links; and cisplatin is a platinum-based antineoplastic agent that creates DNA adducts. Together, these agents aim to inhibit DNA replication and induce apoptosis in aggressive thyroid malignancies.
- Other names
- CAP regimenCIS-DOX-CYC
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on doxorubicin + cyclophosphamide + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + cyclophosphamide + cisplatin.